Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

General Information


Ra’anana, ISR
13 HaSadna Street
POBox 2397
Ra’anana, ISR


Series A, 5/2013



heraCoat is a clinical stage specialty pharmaceutical company focused on innovative drug-delivery solutions for the treatment of intra-cavital diseases. TheraCoat technology enables control on the pharmacokinetics of off-the-shelf drugs resulting in an optimized Therapeutic Index without changing the drug molecular structure.

TheraCoat is currently focused on local treatments of bladder diseases – such as non-muscle-invasive bladder cancer (NMIBC), upper tract urothelial carcinoma (UTUC) and overactive bladder (OAB) – treatments that together address over 300 million patients worldwide.

TheraCoat sustained release treatments enable controlled and longer exposure of bladder tissue to medications as compared to standard intravesical instillations. Pre-clinical results have shown over ten-fold higher drug concentration in the bladder tissue and significantly lower levels in the plasma, indicating a potential for significantly higher efficacy and better safety.

TheraCoat core capabilities are based on using a family of proprietary hydrogels that have ideal properties for deployment of medications into the bladder.

TheraCoat has commenced clinical studies of intravesical instillation with sustained release of chemotherapy for NMIBC and a neurotoxin for OAB.

TheraCoat has been granted CE Mark clearance as a Medical Device.

Recent Milestones

  • Dollar
    TheraCoat received $7M in Series A funding. (5/21/13)
    Posted 5/22/13 at 10:08pm via



TheraCoat screenshot
Above: Homepage
Uploaded: 5/23/13


  1. Bladder treatment co TheraCoat raises $7m ( [edit]
Edit This Page
Last Edited 5/22/13

Revision History RSS Picture


Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API


Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy